Advertisement
Advertisement
NKTR
Nektar Therapeutics
68.58
USDSponsored
-0.91
-1.31%
May 21, 16:00 UTC -4
Closed
After-Market
69.00
+0.42
+0.61%
NKTR Earnings Reports
Positive Surprise Ratio
NKTR beat 33 of 42 last estimates.
79%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$10.59M
/-$2.07
Implied change from Q1 26 (Revenue/ EPS)
-2.52%
/+13.74%
Implied change from Q2 25 (Revenue/ EPS)
-5.26%
/-29.83%
Nektar Therapeutics earnings per share and revenue
On May 07, 2026, NKTR reported earnings of -1.82 USD per share (EPS) for Q1 26, missing the estimate of -1.62 USD, resulting in a -11.88% surprise. Revenue reached 10.86 million, compared to an expected 10.85 million, with a 0.11% difference. The market reacted with a -1.78% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -2.07 USD, with revenue projected to reach 10.59 million USD, implying an increase of 13.74% EPS, and decrease of -2.52% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.61
Surprise
-13.81%
ProKidney Corp. Class A Ordinary Shares
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+0.57%
Galectin Therapeutics Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.08
Surprise
-30.72%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
$0.29
Actual
-$0.04
Surprise
-113.64%
Incannex Healthcare Limited - ADR
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.94
Actual
-$11.22
Surprise
-1088.38%
VYNE Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.08
Surprise
+56.43%
Wellgistics Health, Inc. Common Stock
Report Date
May 19, 2026 For Q1 26
Estimate
-Actual
-$0.07
Surprise
-
Traws Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.75
Actual
-$0.53
Surprise
+29.78%
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.77
Actual
-$1.28
Surprise
-65.12%
AIM ImmunoTech Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.37
Actual
-$0.56
Surprise
-52.53%
FAQ
What were Nektar Therapeutics's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Nektar Therapeutics reported EPS of -$1.82, missing estimates by -11.88%, and revenue of $10.86M, 0.11% above expectations.
How did the market react to Nektar Therapeutics's Q1 2026 earnings?
The stock price moved down -1.78%, changed from $83.37 before the earnings release to $81.89 the day after.
When is Nektar Therapeutics expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Nektar Therapeutics's next earnings report?
Based on 8
analysts, Nektar Therapeutics is expected to report EPS of -$2.07 and revenue of $10.59M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement